Patents by Inventor Robert J. Danaher

Robert J. Danaher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6573041
    Abstract: We previously described a novel in vitro model of a non-productive herpes simplex virus type 1 (HSV-1) infection in neurally-differentiated (ND)-PC12 cells that allows for inducible virus replication upon forskolin and heat stress (HS) treatment. In this research, we further characterized the model with respect to HSV-2 strain 333. We found that: (i) ND-PC12 cells are non-permissive to HSV-2 replication; (ii) HSV-2 can establish a quiescent infection, like HSV-1, in ND-PC12 cells with the transient use of acycloguanosine (ACV); however unlike HSV-1, anti-viral conditions are not obligatory to establish and maintain a quiescent state; (iii) the quiescent state is maintained in the presence of Vero cell cocultivation indicating that such cultures are free of infectious virus; and (iv) a high percentage of quiescently infected (QIF)-PC 12 cell cultures (80-100%) produce HSV-2 in response to forskolin and HS (43° C., 3 h) treatment for as long as 4 weeks post infection.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: June 3, 2003
    Assignee: University of Kentucky Research Foundation
    Inventors: Craig S. Miller, Robert J. Jacob, Robert J. Danaher
  • Publication number: 20030032006
    Abstract: We previously described a novel in vitro model of a non-productive herpes simplex virus type 1 (HSV-1) infection in neurally-differentiated (ND)-PC12 cells that allows for inducible virus replication upon forskolin and heat stress (HS) treatment. In this research, we further characterized the model with respect to HSV-2 strain 333. We found that: (i) ND-PC12 cells are non-permissive to HSV-2 replication; (ii) HSV-2 can establish a quiescent infection, like HSV-1, in ND-PC 12 cells with the transient use of acycloguanosine (ACV); however unlike HSV-1, anti-viral conditions are not obligatory to establish and maintain a quiescent state; (iii) the quiescent state is maintained in the presence of Vero cell cocultivation indicating that such cultures are free of infectious virus; and (iv) a high percentage of quiescently infected (QIF)-PC 12 cell cultures (80-100%) produce HSV-2 in response to forskolin and HS (43° C., 3 h) treatment for as long as 4 weeks post infection.
    Type: Application
    Filed: October 29, 2001
    Publication date: February 13, 2003
    Inventors: Craig S. Miller, Robert J. Jacob, Robert J. Danaher
  • Patent number: 6268124
    Abstract: The present invention provides, inter alia, a PC12 cell quiescently infected with a neurotropic virus. Preferred quiescently-infected neural cells are those wherein the neurotropic virus is a neurotropic herpes virus. Methods related to these and other materials are also provided.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: July 31, 2001
    Assignee: University of Kentucky Research Foundation
    Inventors: Craig S. Miller, Robert J. Danaher, Robert J. Jacob